- Home
- BJDX vs ENVB Comparison
BJDX vs ENVB Comparison
Compare BJDX & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BJDX
- ENVB
- Stock Information
- Founded
- BJDX 2015
- ENVB 1994
- Country
- BJDX United States
- ENVB United States
- Employees
- BJDX N/A
- ENVB N/A
- Industry
- BJDX Medical Specialities
- ENVB Biotechnology: Pharmaceutical Preparations
- Sector
- BJDX Health Care
- ENVB Health Care
- Exchange
- BJDX Nasdaq
- ENVB Nasdaq
- Market Cap
- BJDX 2.9M
- ENVB 3.1M
- IPO Year
- BJDX 2021
- ENVB N/A
- Fundamental
- Price
- BJDX $1.58
- ENVB $1.25
- Analyst Decision
- BJDX
- ENVB Strong Buy
- Analyst Count
- BJDX 0
- ENVB 1
- Target Price
- BJDX N/A
- ENVB $10.00
- AVG Volume (30 Days)
- BJDX 2.1M
- ENVB 184.2K
- Earning Date
- BJDX 08-13-2025
- ENVB 08-11-2025
- Dividend Yield
- BJDX N/A
- ENVB N/A
- EPS Growth
- BJDX N/A
- ENVB N/A
- EPS
- BJDX N/A
- ENVB N/A
- Revenue
- BJDX N/A
- ENVB N/A
- Revenue This Year
- BJDX N/A
- ENVB N/A
- Revenue Next Year
- BJDX $55.56
- ENVB N/A
- P/E Ratio
- BJDX N/A
- ENVB N/A
- Revenue Growth
- BJDX N/A
- ENVB N/A
- 52 Week Low
- BJDX $1.46
- ENVB $1.01
- 52 Week High
- BJDX $44.50
- ENVB $11.55
- Technical
- Relative Strength Index (RSI)
- BJDX 42.16
- ENVB 44.83
- Support Level
- BJDX $1.49
- ENVB $1.20
- Resistance Level
- BJDX $1.63
- ENVB $1.35
- Average True Range (ATR)
- BJDX 0.16
- ENVB 0.07
- MACD
- BJDX -0.00
- ENVB 0.01
- Stochastic Oscillator
- BJDX 7.29
- ENVB 38.89
About BJDX Bluejay Diagnostics Inc.
Bluejay Diagnostics Inc is a medical diagnostics company. It is developing rapid tests using whole blood using its Symphony technology platform to improve patient outcomes in critical care settings. The company's first product, the Symphony IL-6 test, is for the monitoring of disease progression in critical care settings and is a clinically established inflammatory biomarker for the assessment of the severity of infection and inflammation across many disease indications, including sepsis.
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.